{"protocolSection":{"identificationModule":{"nctId":"NCT00234546","orgStudyIdInfo":{"id":"A-38-52120-713"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity","officialTitle":"A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke."},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2003-02"},"completionDateStruct":{"date":"2007-10","type":"ACTUAL"},"studyFirstSubmitDate":"2005-10-06","studyFirstSubmitQcDate":"2005-10-06","studyFirstPostDateStruct":{"date":"2005-10-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-07-25","lastUpdatePostDateStruct":{"date":"2019-07-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke."},"conditionsModule":{"conditions":["Muscle Spasticity","Cerebrovascular Accident"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":162,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Dysport","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"2","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","description":"1 injection, 500 U at day 0. The study will last for 6 months in each patient.","armGroupLabels":["1"],"otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"type":"DRUG","name":"Placebo","description":"1 injection at day 0. The study will last for 6 months in each patient.","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Reduction of spasticity assessed by changes of the Modified Ashworth Spasticity Score from baseline of elbow and wrist flexors in supine anatomical position","timeFrame":"week 4"}],"secondaryOutcomes":[{"measure":"Improvement of neurologic outcome (mobility and function), evaluated by Modified Ashworth Scale, Barthel Index, Modified Rankin scale, Functional scale (Motor Assessment Scale)","timeFrame":"weeks 4, 8, 12 & 24"},{"measure":"Voluntary and passive joint range of motion goniometer assessment","timeFrame":"weeks 4, 8, 12 & 24"},{"measure":"Pain Assessment using visual analogue scale for pain","timeFrame":"weeks 4, 8, 12 & 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* First-ever stroke according to the World Health Organisation criteria (previous transient ischaemic attack or clinically silent infarct on CT/MRI is not counted as previous stroke)\n* CT/MRI scan required to classify ischaemic / haemorrhagic stroke\n* Patient recruited 2-12 weeks after stroke\n* Modified Ashworth Spasticity Score 1+ or above in either elbow or wrist joint\n\nExclusion Criteria:\n\n* The patient has bleeding disturbances or having used coumarin derivatives\n* The patient is currently receiving drugs affecting neuromuscular transmission\n* Co-existing severe systemic illness which may adversely affect the functional outcome\n* Pre-existing neuromuscular junction disease or any neurogenic disorders which can interfere with spasticity","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Prince of Wales Hospital","city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"facility":"University Hospital of Malaya Medical Centre","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"University of Santo Tomas","city":"Manila","zip":"3001 MAB","country":"Philippines","geoPoint":{"lat":14.6042,"lon":120.9822}},{"facility":"TTSH Rehabilitation Centre","city":"Singapore","zip":"569766","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Siriraj Hospital","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}}]},"referencesModule":{"references":[{"pmid":"22371239","type":"RESULT","citation":"Rosales RL, Kong KH, Goh KJ, Kumthornthip W, Mok VC, Delgado-De Los Santos MM, Chua KS, Abdullah SJ, Zakine B, Maisonobe P, Magis A, Wong KS. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012 Sep;26(7):812-21. doi: 10.1177/1545968311430824. Epub 2012 Feb 27."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Korea, Republic of"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Baricitinib","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}